Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants

Convalescent COVID-19 plasma donor selection and lymphocyte isolation

Convalescent COVID-19 plasma donors were prospectively enrolled onto an institutional review board-approved protocol (Clinical Trials Registration, NCT04360278)¹⁹ and provided written informed consent for the study. Among them, 12 convalescent plasma donors with high titer neutralizing antibodies against SARS-CoV2 were selected and 20-40 ml of blood was collected from each of the 12 donors. Eligibility criteria included molecular or serologic laboratory evidence of past COVID-19 infection, and complete recovery from COVID-19, with no symptoms for ≥28 days or ≥14 days with a negative molecular test after recovery. PBMCs were prepared using density centrifugation on a Ficoll-Paque gradient.

Live virus neutralization assay used in COVID-19 convalescent patients

Neutralization of live virus by patient plasmas was tested using a fluorescence reduction neutralization assay (FRNA) with SARS-CoV-2 [2019-nCoV/USA-WA1-A12/2020 (WA-1) from the US Centers for Disease Control and Prevention, Atlanta, GA, USA] at the NIH-NIAID Integrated Research Facility at Fort Detrick, MD, USA, as previously reported³⁹. In these experiments, a fixed volume of diluted virus was incubated with an equivalent volume of test plasma for 1 hour at 37 °C prior to adding the suspension to Vero E6 cells (ATCC, Manassas, VA, USA, #CRL-1586). The virus was allowed to propagate for 24 hours prior to fixing the cells. Following fixation, the cells were permeabilized and probed with a SARS-CoV-2 nucleoprotein-specific rabbit primary antibody (Sino Biological, Wayne, PA, USA, #40143- R001) followed by an Alexa594-conjugated secondary antibody (Life Technologies, San Diego, CA, USA, #A11037). The total number of infected cells in four fields per well with each field containing at least 1000 cells was quantified using an Operetta high content imaging system (Perkin Elmer, Waltham, MA, USA). Plasma was tested using two-fold serial dilutions from 1:40 to 1:1280 with four replicates per dilution. Results were calculated as the highest dilution of plasma leading to at least 50% reduction of SARS-CoV-2 titers. Each assay was controlled with internal addition of an S-specific neutralizing polyclonal antibodies. If a 1:40 dilution did not lead to at least 50% reduction of viral titer, results were reported as <1:40 even though some inhibition of virus propagation may have been present. To enable analysis of nAb kinetics over time, a value of 1:20 was used as a surrogate for results <1:40 since this value was the next serial 2-fold titer below the lowest positive result.

Human Fab antibody library construction

Total RNA was extracted from PBMCs using RNeasy mini kit (Qiagen) and 1^st strand cDNA was reverse transcribed with oligo(dT) as a primer with a kit from GE Healthcare and used as a template for antibody Fab coding fragment amplification. Briefly, the γ1 heavy chain Fd (variable and first constant region) was amplified with nine human heavy chain–specific 5′ primers and a human γ1–specific 3′ primer. The κ chain was amplified by PCR with seven human κ chain–specific 5′ primers and a 3′ primer matching the end of the constant region⁴⁰. The λ chain was amplified by PCR with six human λ chain–specific 5′ primers and a 3′ primer matching the end of the constant region⁴¹. PCR was performed for 30 cycles at 95 °C for1 min, 52 °C for 1 min, and 72 °C for 1 min with AmpliTaq DNA polymerase (Applied Biosystems).

Amplified κ and λ chain DNA fragments were pooled, purified, digested with SacI and XbaI. The restriction enzyme digested light chain fragments from one donor or pooled from 5 donors were then cloned into the pComb 3H vector by electroporation⁴². The recombinant plasmid DNA was introduced into Escherichia coli Top 10 cells (Invitrogen) by electroporation, yielding 1 × 10⁷ individual clones. The plasmid DNA containing light chain sequences was digested with XhoI and SpeI, ligated with γ1 Fd DNA cut with the same enzymes. The plasmid DNAs containing light and heavy chains were transformed into E. coli Top 10 cells by electroporation.

Four phage display Fab libraries with average size of 5 × 10⁸ individual clones for each library were generated.

Expression and purification of recombinant SARS-CoV-2 spike protein trimers

The stabilized SARS-Cov-2 spike protein trimer (S-2P) was produced by transient transfection of 293 Freestyle cells as previously described²⁰. One liter of 293 Freestyle cells at concentration of about 0.9 million cells per ml was transfected with 1 mg of S-2P plasmid, pre-mixed with 1 ml of 293fectin™ Transfection Reagent. The cells were allowed to grow for 6-7 days at 125 rpm, 37 °C, and 8 % CO2; then the supernatant was harvested by centrifugation and filtered through Millipore Sigma 0.22 um PES filter. The cleared supernatant was incubated with 5 mL of HisPur™ Ni-NTA Resin ThermoFisher for three hours, then the resin was collected and washed with PBS with 25 mM imidazole, pH 7.4. The captured SARS-CoV-2 S S-2P was eluted by PBS with 250 mM imidazole, pH 7.4. After elution, the trimeric protein was collected, concentrated and applied to a Superdex 200 16/60 gel filtration column equilibrated with PBS. Peak fractions were pooled and concentrated to 1 mg/mL. The SARS-CoV-2 S-6P trimer was expressed and purified as previously described³³. Briefly, 1 mg of DNA encoding the S-6P spike was transfected into 293 Freestyle cells using Turbo293 transfection reagent. The cells were grown at 37°C for 6 days, after which the supernatant was harvested and applied to His-Pure affinity resin. The resin was washed with 20 mM imidazole in PBS, and the protein eluted with 20 mM HEPES, pH 7.5, 200 mM NaCl and 300 mM imidazole. The trimeric protein was further purified on a Superdex S-200 gel filtration column equilibrated in PBS and concentrated to 1 mg/ml and flash frozen in liquid nitrogen for storage at -80°C.

Selection of specific Fab clones

For phage production, 25 ml of logarithmic bacteria culture (OD600=0.6) in 2×TY supplemented with 100 μg/mL ampicillin and 2% glucose (2×TY-Amp-Glu) were infected with M13KO7 helper phage (New England Biolabs, USA) at 7×10⁹ plaque forming unit (PFU) per ml (∼1:20 multiplicity of infection) by incubating at 37°C for 30 min without shaking, followed by 30 min at 120 rpm. Infected cells were harvested by centrifugation (5000 g for 5 min) and resuspended in 100 ml 2×TY supplemented with 100 μg/mL ampicillin and 50 μg/mL kanamycin. After overnight growth at 30°C at 250 rpm, the cells were removed by centrifugation (18000 g at 4°C for 20 min). The culture supernatant containing the phages was filtered through a 0.45-μm filter and then precipitated with 1/5 volume of 20% PEG8000 (polyethylene glycol) in a 2.5 M NaCl solution, for 1 h on ice. Phage particles were pelleted by centrifugation (9000 g at 4°C for 20 min) and re-dissolved in 1 mL 1×PBS.

The phage library was panned by affinity binding of Fab-expressing phages on S-2P coated on the wells of an ELISA plate. Blocking of plates and phages was conducted for 60 min using 3% skimmed milk in 1×PBS. All washing steps were performed using PBS containing 0.05% Tween20 (PBST). For each panning cycle, 1 μg/mL antigen was used to coat the polystyrene plate and after an overnight incubation, plates were washed and blocked. For the first panning cycle, approximately 1×10¹¹ phages were incubated with the antigen coated plates for 2 h, followed by a total of 20 washes with PBST. The eluted phages were amplified in E. coli Top 10 cells. Bacterial culture was plated on 2×TY-Amp-Glu agar and incubated overnight at 30°C. Clones were harvested into 5 ml 2×TY-Amp-Glu and phage production for the next round of panning, which was conducted in 40 ml medium, as described above. Two additional panning cycles were repeated using the same protocol. Following three cycles of panning, the selected phages were used for infection of E. coli. Single colonies were randomly picked from the third cycle output and screening of specific binders was performed, using phage ELISA against S-2P, with a BSA coated-plate as a negative control.

Sequence analysis of S-2P-positive Fab clones

We sequenced the heavy-chain variable region (VH-DH-JH genes) of the ELISA-positive SARS-CoV-2 S-2P- specific clones obtained from each library using the Applied BioSystems model 3730 automated DNA sequencer with a modified Sanger method. The closest human germline V(D)J gene segments for each unique sequence were determined using DNAPLOT with IMGT sequence database (http://www.imgt.org/IMGT). The framework and CDRs were assigned according to IMGT nomenclature. The somatic mutations were identified by comparison of V-genes (from framework 1 to 3) with the closest germline counterpart. The first 28 nucleotides corresponding to the primer sequence were not included in the analysis. The distribution of VH and JH gene usage and HCDR3 length of anti-HBc was analyzed.

Expression and purification of Fab and IgG

The phagemid containing light chain and heavy chain was cleaved with NheI and SpeI and re- circularized after removal of the phage gene III DNA fragment from the vector to encode soluble Fab. Bacteria containing circularized DNA without phage gene III were cultured in 2×TY medium containing 2% glucose, 100 µg/mL ampicillin, and 15 µg/mL tetracycline at 30°C until the OD600 reached 0.5–1. The culture was diluted 5-fold in 2×YT medium without glucose and containing 0.2 mM isopropyl β-D-thiogalactoside (IPTG), and culture was continued at 27°C for 20 h for expression of soluble Fab. Because the Fab was tagged at the C terminus with (His)6, the expressed proteins were affinity-purified on a nickel-charged column and were further purified through a cation-exchange SP column (Cytiva).

For IgG production, Expi293F™ cells (Thermo Fisher) were transiently transfected with plasmids carrying the antibody heavy chain and light chains. Cells were grown for six days at 37°C with 8% CO2 shaking at 125 rpm according to the manufacturer’s protocol (Thermo Fisher). Cell cultures were harvested six days after transfection and centrifuged at 20,000 g for 30 min at 4°C. The supernatants were collected and filtrated through a 0.22 µm filter. The expressed IgGs were purified by affinity chromatography on an immobilized protein G column (Cytiva). The purity of the Fab and IgG was evaluated by sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE), and the protein concentrations were determined by optical density (OD) measurements at 280 nm, with an A280 of 1.5 corresponding to 1.0 mg/mL.

ELISA assays

For conventional antigen-binding ELISA, 96-well plates were coated with 100 µl/well containing 1 µg/ml protein in 1×PBS (pH 7.4) and incubated at room temperature overnight. Serial dilutions of soluble Fab, IgG, or phage were added to the wells, and plates were incubated for 2 h at room temperature. The plates were washed, and the secondary conjugated antibody (anti-His-HRP, anti-human Fab-HRP, or anti-M13-HRP) was added and incubated for 1 h at room temperature. The plates were washed, and the color was developed by adding tetramethylbenzidine reagent (KPL; Gaithersburg, MD), and the development was stopped with H2SO4 after 10 min. The plates were read at OD450 in an ELISA plate reader. The data were plotted, and the dose-response curves were generated with Prism software (Graphpad Software, Inc., San Diego, CA).

For RBD-competition ELISA, 96-well plates were coated with 100 µl/well containing 1 µg/mL of recombinant S-2P trimer in 1×PBS (pH 7.4), and the plates were incubated at room temperature overnight. Each Fab was 3-fold serially diluted from a starting concentration of 3 µg/mL in 3% milk/PBS or in 3% milk/PBS containing recombinant RBD protein (Sino Biological #40592-V08B) at fixed concentration (5 µg/mL). Following incubation for 2 h at room temperature, the plate was washed, and a secondary anti-human Fab-HRP antibody (Jackson ImmunoResearch) was added for 1 h at room temperature. The plate was then washed, and the reaction was developed by adding tetramethylbenzidine substrate (KPL; Gaithersburg, MD). The reaction was stopped after 10 min by addition of sulfuric acid. The plates were read at OD450 in an ELISA plate reader. The data were plotted, and dose-response curves with and without inhibition with RBD were generated using Prism software (Graphpad Software, Inc., San Diego, CA).

For antibody cross-competition ELISA, 96-well ELISA plates were coated with 100µl/well containing 1 µg/mL of recombinant S-2P trimer in 1×PBS (pH 7.4) and the plates were incubated at room temperature overnight. To test cross-competition among the mAbs, the IgG version of each mAb was incubated at 0.1 µg/ml with each of 11 Fabs at 1 µg/ml. An in house- produced anti-poliovirus IgG antibody was used as a negative control⁴³. Following incubation for 2 h at room temperature, the plates were washed, and a secondary anti-human IgG Fc-HRP antibody (Jackson ImmunoResearch) was added and incubated for 1 h at room temperature. The plates were then washed, and the reaction was developed by adding tetramethylbenzidine substrate (KPL; Gaithersburg, MD). The reaction was stopped after 10 min by addition of sulfuric acid. The plates were read at OD450 in an ELISA plate reader. The average value from three wells was used to calculate the percent competition using the following formula: [1- (average OD from wells containing test IgG with Fab – average OD from control wells)/(average OD from wells containing test IgG without Fab – average OD from control wells)] x100%.

Surface plasmon resonance (SPR)

The SPR experiments were performed on a Biacore™ T200 (Cytiva) at 25 °C in 10 mM HEPES pH 7.2, 150 mM NaCl, 3 mM EDTA, 0.05% Tween-20. The recombinant SARS-CoV-2 spike 2p (S-2P) protein was immobilized on a Series S-CM5 sensor chip (Cytiva) by amine coupling (NHS/EDC) to flow cells. A mock coupled surface was used for background subtraction.

Binding and kinetics studies were performed multiple times for each Fab. Increasing amounts of each Fab were injected over the surface at a flow rate of 30 μl/min with an association time of 120 sec and dissociation time of 180 sec, followed by a regeneration with 100mM CAPS, pH 11.5 for 90 sec. Binding data were analyzed using Biacore™ T200 Evaluation Software 3.1 (Biaeval) with fits to the Langmuir binding equation for a 1:1 interaction model. In addition, data were analyzed by surface site affinity distribution analysis by EVILFIT⁴⁴. Values obtained with the two methods were consistent.

Pseudotype neutralization assay

The SARS-Cov-2 pseudovirus neutralization assays were performed as previously reported⁴⁵. Briefly, single-round luciferase-expressing pseudoviruses were generated by co-transfection of plasmids encoding the full-length SARS-CoV-2 S protein (Wuhan-1, GenBank accession number, MN908947.3; B.1.351/Beta; B.1.1.7/Alpha; B.1.617.2./Delta; B.1.1.529/Omicron; luciferase (pHR’ CMV Luc), a lentivirus backbone (pCMV ΔR8.2), and human transmembrane protease serine 2 (TMPRSS2) at a ratio of 1:20:20:0.3 into HEK293T/17 cells (ATCC) using the transfection reagent LiFect293™. The pseudoviruses were harvested after 72 hours. The supernatants were collected by centrifugation at 1500 rpm for 10 minutes, then filtered through a 0.45 µM filter, aliquoted and titrated before the neutralization assay. To test antibody-mediated neutralization, an 8-point, 5-fold dilution series was prepared for each antibody in culture medium (DMEM medium supplemented with 10% fetal bovine serum, 1% penicillin- streptomycin and 3 µg/mL puromycin). Each antibody dilution (50 µL) was mixed with 50 µL of diluted pseudovirus in 96-well plates and incubated for 30 min at 37°C. The mixture was then incubated with 10⁴ ACE-2-expressing 293T cells (293T-hACE2.MF) in a final volume of 200 µL. 72 hours later, the supernatant was carefully removing, the cells were lysed with Bright- Glo™ Luciferase Assay substrate (Promega), and the luciferase activity (relative light units, RLU) was measured. Percent neutralization was normalized considering uninfected cells as 100% neutralization and cells infected in the absence of antibodies as 0% neutralization. IC50 titers were determined using a log (agonist) vs. normalized response (variable slope) nonlinear function in Prism v8 (GraphPad).

Live Virus Neutralization Assay of hamster sera

SARS-CoV-2 neutralization using live virus was determined in the BSL3 laboratory using SARS-CoV-2 USA-WA1/2020 (WA-1; GenBank MN985325; GISAID: EPI_ISL_404895; obtained from Dr. Natalie Thornburg, Centers for Disease Control and Prevention (CDC)) and USA/MD-HP01542/2021 (lineage B.1.351/Beta variant; GISAID: EPI_ISL_890360; obtained from Dr. Andrew Pekosz, Johns Hopkins University). WA-1 was passaged twice on Vero E6 cells. The USA/MD-HP01542/2021 was passaged on TMPRSS2-expressing Vero E6 cells. The SARS-CoV-2 stocks were titrated in Vero E6 cells by determination of the 50% tissue culture infectious dose (TCID50) as previously described⁴⁶.

The mAbs were serially diluted in Opti-MEM and mixed with an equal volume of SARS-CoV-2 (100 TCID50) and then incubated at 37°C for 1 h. Mixtures were added to quadruplicate wells of Vero E6 cells in 96-well plates and incubated for four days. The 50% neutralizing dose (ND50) was defined as the highest dilution of serum that completely prevented cytopathic effect in 50% of the wells and was expressed as a log10 reciprocal value⁴⁷. The dilution of serum that completely prevented cytopathic effect in 50% of the wells (ND50) was calculated by the Reed and Muench formula⁴⁸.

Prophylactic and therapeutic studies in the hamster model

The preclinical hamster studies were approved by the NIAID Animal Care and Use Committee. All the animal experiments were carried out following the Guide for the Care and Use of Laboratory Animals by the NIH. Golden Syrian hamsters (Mesocricetus auratus, Envigo Laboratories, Frederick, MD) were used in experiments conducted in BSL2 and BSL3 facilities approved by the USDA and CDC. In the prophylactic study, 80 male Syrian hamsters, aged 8-9 weeks, were randomly divided into groups of 10 animals each, bled for baseline serology and inoculated intraperitoneally with 0.5 mL of NE12, NA8, or IgG1 control at 12 mg/kg or 4 mg/kg, diluted to the concentration of 2.4 mg/mL or 0.8 mg/mL in PBS. Twenty-four hours later, the animals were challenged intranasally with 4.5 log10 TCID50 of SARS-CoV-2 WA-1 or B.1.351 in 100 µL volumes of L-15 medium (ThermoFisher) per animal. Intranasal instillations were performed under light isoflurane anesthesia. Animals were euthanized by CO2 inhalation prior to necropsy. Body weights and clinical symptoms were monitored daily from day -3 before challenge through day 5 after challenge. On days 3 and 5 post-challenge, 5 animals per group were necropsied; nasal turbinate and lung tissues were collected. Tissues were weighed, mixed with L-15 medium (10 mL per gram of tissue), homogenized, and clarified by centrifugation. Aliquots were snap-frozen and stored at -80°C. The presence of the challenge virus in clarified tissue homogenates was evaluated by limiting-dilution titrations on Vero E6 cells. The titration of SARS-CoV-2 was performed by determination of the TCID50 in Vero E6 cells and expressed as TCID50 per gram of tissue, as previously described⁴⁶.

In the therapeutic study, 60 male Syrian hamsters, aged 9-10 weeks, were randomly divided into three groups of 10 animals each, bled for serology and inoculated intranasally with 4.5 log10 TCID50 of SARS-CoV-2 WA-1 or B.1.351 in 100 µL volumes per animal. Twenty-four hours later, the animals were inoculated intraperitoneally with 0.5 mL of NE12, NA8, or IgG1 control at 12 mg/kg, diluted to the concentration of 2.4 mg/mL in PBS. Body weights and clinical symptoms were monitored daily from day -4 before virus inoculation through day 11 after inoculation. On day 3 post-inoculation, five animals per group were necropsied; nasal turbinates and lungs were collected and processed as above. Virus titers were determined by limiting-dilution titrations on Vero E6 cells as described above.

Statistical analysis

Data sets were assessed for significance using one-way ANOVA with Tukey’s multiple comparison test, or, if indicated, by non-parametric Kruskal-Wallis test with a Benjamini, Krieger and Yekutieli false-discovery test. Statistical comparisons of weight changes between treatment groups were performed using a repeated-measures mixed-effects model with Tukey’s multiple-comparison test. Data were only considered significant at p < 0.05. Analyses were performed using Prism 9 (GraphPad Software).

Cryo-EM specimen preparation and data collection

SARS-CoV-2 S-6P spike at a concentration of 0.5 mg/ml in PBS was mixed with Fab NA8 or Fab NE12 using a Fab-to-RBD molar ratio of 1:1, and the complex was used for specimen preparation after a brief (5-10 min) incubation at 4°C. To prepare cryo-EM specimens, Quantifoil R 2/2 gold grids were glow-discharged using a PELCO easiGlow device (air pressure: 0.39 mBar, current: 20 mA, duration: 30 s) immediately before vitrification using an FEI Vitrobot Mark IV plunger. The Vitrobot chamber was kept at 4°C and 95% humidity, and the drop volume was 2.7 µl. Datasets were collected at the National CryoEM Facility (NCEF), National Cancer Institute, using a Thermo Scientific Titan Krios G3 electron microscope equipped with a K3 direct electron detector and Gatan Quantum GIF energy filter (slit width: 20 eV) (Extended Data Table 4).

Single particle analysis of cryo-EM data

Single particle analysis was performed using the Frederick Research Computing Environment (FRCE) computing cluster. MotionCorr2 was used for patch-based movie frame alignment⁴⁹. Contrast transfer function parameters were estimated with ctffind 4.1⁵⁰. The following steps were performed using Relion 3.1.0⁵¹, unless otherwise stated. Particle picking was performed using the template-free Laplacian-Gaussian filter-based approach. Particles were first extracted with 4x binning and subjected to 2D and 3D classification, with the low-pass filtered cryo-EM map of individual SARS-CoV-2 S-2P spike at pH 7.4 serving as the initial 3D model. Particles contributing to high-quality 3D classes were then re-extracted with 2x binning, and the above procedure was repeated. Finally, the best particles were re-extracted without binning, and the 3D map was iteratively improved with rounds of 3D auto-refinement, CTF refinement, and Bayesian polishing. For local refinement, a soft mask encompassing one RBD in the down position with the bound Fab and the neighboring NTD was created after segmenting the refined ensemble map in UCSF Chimera⁵² and used for auto-refinement with limited angular search (-sigma_ang = 5). Resolution was calculated using the gold-standard approach⁵³ at the FSC curve threshold of 0.143. Local resolution was determined with ResMap 1.1.4⁵⁴.

Atomic model generation

An RBD from the cryo-EM structure of the S-2P spike at pH 4.0 (PDB ID 6xlu) was docked into the locally refined cryo-EM map, along with an NTD from the same structure and a homology model of the corresponding Fab prepared using the SWISS-MODEL server⁵⁵. The atomic model was refined by alternating rounds of model building in Coot⁵⁶ and real-space refinement in Phenix⁵⁷. Structure validation was performed with Molprobity⁵⁸. Map-model correlations were evaluated with phenix.mtriage⁵⁹. Molecular graphics and analyses were performed with UCSF Chimera⁶⁰.